Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicentre study to optimize therapy of B-ALL and high grade non-Hodgkin lymphoma in adults
2009-012950-19Phase 4Completed
- Sponsor
- Northern Italy Leukemia Group
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in Burkitt lymphoma (BL) and Burkitt leukemia, sponsored by Northern Italy Leukemia Group. Primary endpoints: Remission rate, Remission duration and 2 more. Started Nov 2009; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemia
Beyond the preview
Go deeper on 2009-012950-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012950-19.